ADVENZYMES - Advanced Enzyme
📢 Recent Corporate Announcements
Advanced Enzyme Technologies Limited has announced the resignation of Mr. Dipak Roda, the Senior Vice President of Marketing and Business Development. The resignation was tendered on March 10, 2026, and is scheduled to take effect from the close of business hours on April 09, 2026. As a key member of the senior management team, his departure marks a transition in the company's marketing leadership. The company has complied with SEBI Regulation 30 in disclosing this management change to the exchanges.
- Mr. Dipak Roda resigned from his role as Senior Vice President - Marketing and Business Development on March 10, 2026.
- The official cessation of his duties is set for the close of business hours on April 09, 2026.
- The disclosure was made in accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The company has not yet announced a successor for the Marketing and Business Development portfolio.
Advanced Enzyme Technologies Limited has received high-grade credit ratings from ICRA for its bank facilities totaling ₹100 crore. The long-term fund-based facilities of ₹40 crore were assigned an [ICRA]AA- rating with a Stable outlook, indicating a high degree of safety. Short-term non-fund based limits of ₹15 crore received the highest [ICRA]A1+ rating, reflecting very strong credit quality. Additionally, ₹45 crore in unallocated limits were assigned dual [ICRA]AA- and [ICRA]A1+ ratings.
- ICRA assigned [ICRA]AA- (Stable) rating for ₹40 crore long-term fund-based cash credit facilities.
- Short-term non-fund based limits of ₹15 crore received the highest [ICRA]A1+ rating.
- Unallocated limits of ₹45 crore were assigned dual ratings of [ICRA]AA- (Stable) and [ICRA]A1+.
- The total bank instrument amount rated by ICRA stands at ₹100 crore.
- Ratings reflect a high degree of safety regarding timely servicing of financial obligations and very low credit risk.
Advanced Enzyme Technologies reported a 2% YoY revenue growth to ₹1,719 million for Q3 FY26, though sequential revenue dropped 7%. While PAT increased 11% YoY to ₹432 million, EBITDA fell 11% YoY with margins contracting to 29% from 33% due to weakness in the Human Healthcare segment. Animal Healthcare and Bioprocessing segments provided support with 22% and 13% YoY growth, respectively. Management remains confident in full-year targets despite global trade disruptions and tariff shifts.
- Q3 FY26 Revenue reached ₹1,719 million, up 2% YoY but down 7% sequentially.
- PAT for the quarter rose 11% YoY to ₹432 million with a 25% PAT margin.
- EBITDA declined 11% YoY to ₹494 million, impacted by lower sales in Pharma and Nutrition.
- Animal Healthcare segment grew 22% YoY to ₹241 million, contributing 14% of total revenue.
- 9M FY26 performance remains strong with revenue up 15% and PAT up 20% YoY.
Advanced Enzyme Technologies has officially released the audio recording of its conference call held on February 4, 2026. The call focused on the un-audited financial results for the quarter and nine-month period ended December 31, 2025. This is a standard regulatory filing under SEBI (LODR) Regulations to ensure transparency for all shareholders. Investors can access the recording on the company's website, with a written transcript expected to follow shortly.
- Audio recording of the Q3 FY26 earnings call is now available on the company's investor portal.
- The conference call was conducted on February 4, 2026, following the release of un-audited results.
- The discussion covered the company's performance for the nine-month period ending December 31, 2025.
- Management confirmed that a written transcript will be submitted to the stock exchanges in due course.
Advanced Enzyme Technologies' US-based subsidiary, AST, has received a favorable ruling from the US Court of Appeals in a lawsuit filed by World Nutrition Inc. As a result, the company has reversed a previously created provision of ₹159.64 million. This reversal has been accounted for in the financial results for the quarter ended December 31, 2025. This development is expected to positively impact the net profit for the reported quarter by removing a significant legal liability.
- Reversal of ₹159.64 million provision related to the AST lawsuit in the USA.
- Favorable decision received from the United States Court of Appeals for the Ninth Circuit.
- The financial impact is reflected in the un-audited results for the quarter ended December 31, 2025.
- The lawsuit was originally filed by World Nutrition Inc. (WNI) against the step-down subsidiary AST.
- The reversal was noted and approved by the Audit Committee and Board of Directors on January 31, 2026.
Advanced Enzyme Technologies reported a modest 2% YoY revenue growth in Q3 FY26, reaching ₹1,719 million, though revenue declined 7% sequentially. While PAT increased 11% YoY to ₹432 million, EBITDA faced pressure, declining 11% YoY with margins contracting from 33% to 29%. The growth was led by the Animal Nutrition (+22% YoY) and Industrial Bio-processing (+13% YoY) segments, which helped offset a 6% decline in the core Human Nutrition business. Geographically, strong growth in India and Rest of World was partially offset by an 11% decline in the Americas market.
- Consolidated Revenue grew 2% YoY to ₹1,719 million, but declined 7% on a QoQ basis.
- EBITDA de-grew by 11% YoY to ₹494 million, with EBITDA margin standing at 29%.
- PAT increased 11% YoY to ₹432 million, supported by an exceptional gain of ₹112 million.
- Animal Nutrition segment showed strong momentum with 22% YoY growth to ₹241 million.
- 9M FY26 performance remains healthy with Revenue and PAT up 15% and 20% respectively compared to 9M FY25.
Advanced Enzyme Technologies reported a modest 2% YoY revenue growth in Q3 FY26 to ₹1,719 million, though revenue declined 7% sequentially. While PAT grew 11% YoY to ₹432 million, EBITDA margins saw a significant contraction to 29% from 33% in the previous year. The Human Nutrition segment, the company's largest, faced a 6% YoY decline due to weakness in Pharma/API markets, while Animal Nutrition and Bio-Processing showed strong growth of 22% and 13% respectively. For the nine-month period, the company maintains a healthy growth trajectory with PAT up 20% YoY.
- Q3 FY26 Revenue grew 2% YoY to ₹1,719 Mn, but fell 7% QoQ due to Pharma/API weakness.
- PAT increased 11% YoY to ₹432 Mn, while 9M FY26 PAT stands at ₹1,284 Mn, up 20% YoY.
- EBITDA margins compressed to 29% in Q3 FY26 compared to 33% in the same quarter last year.
- Animal Nutrition segment delivered robust 22% YoY growth, reaching ₹241 Mn in Q3 FY26.
- Domestic sales grew 6% YoY to ₹801 Mn, now accounting for 47% of total revenue.
Advanced Enzyme Technologies reported a steady performance for Q3 FY26, with revenue from operations growing 9.1% YoY to ₹1,845.28 million. Net profit for the quarter increased by 11% YoY to ₹431.83 million, although it saw a slight sequential dip from ₹447.33 million in Q2. Strategically, the company has pivoted its renewable energy strategy, opting to acquire up to a 26% stake in a Group Captive Wind Power SPV while cancelling a previously planned solar project. This move is aimed at securing long-term energy cost efficiencies for its manufacturing operations.
- Revenue from operations increased 9.1% YoY to ₹1,845.28 million in Q3 FY26.
- Net profit for the quarter stood at ₹431.83 million, up from ₹388.76 million in the year-ago period.
- Nine-month FY26 revenue reached ₹5,423.90 million with a net profit of ₹1,283.56 million.
- Board approved an investment of up to 26% equity stake in a Special Purpose Vehicle (SPV) for a Group Captive Wind Power Plant.
- The company officially withdrew from a previously proposed group captive solar power project in favor of the wind power initiative.
Advanced Enzyme Technologies reported a steady performance for Q3 FY26, with consolidated revenue growing 7.3% YoY to ₹184.5 crore. Net profit for the quarter increased by 11.1% YoY to ₹43.2 crore, although it saw a slight sequential dip from the previous quarter. The company also announced a strategic shift in its renewable energy plans, opting for a 26% stake in a Group Captive Wind Power Plant instead of a previously planned solar project. For the nine-month period ended December 2025, the company showed robust growth with net profit rising nearly 20% to ₹128.4 crore.
- Consolidated Revenue from operations grew 7.3% YoY to ₹1,845.3 million in Q3 FY26.
- Net Profit for the quarter stood at ₹431.8 million, an 11.1% increase compared to ₹388.8 million in Q3 FY25.
- Nine-month (9M FY26) Net Profit reached ₹1,283.6 million, up 19.7% from ₹1,072.5 million in the previous year.
- Board approved a 26% equity investment in a Group Captive Wind Power SPV, replacing a prior solar project to optimize energy costs.
- Earnings Per Share (EPS) for the quarter improved to ₹3.80 from ₹3.37 in the corresponding quarter last year.
Advanced Enzyme Technologies Limited has scheduled a conference call for analysts and investors on February 4, 2026, at 4:00 PM IST. The call will focus on the company's un-audited financial results for the quarter and nine months ended December 31, 2025. Senior management, including the Whole-time Director and CFO, will be present to discuss operational performance. This is a standard regulatory notification following the conclusion of the third quarter of the fiscal year.
- Conference call scheduled for Wednesday, February 4, 2026, at 16:00 Hours IST.
- Discussion will cover un-audited financial results for the quarter and nine months ended December 31, 2025.
- Management representation includes Mr. Mukund Kabra (Whole-time Director) and Mr. Beni Prasad Rauka (CFO).
- Primary dial-in numbers provided are +91 86 3416 8799 and +91 86 4536 6917.
Advanced Enzyme Technologies Limited has informed the stock exchanges that its statutory auditor, M S K A & Associates, has converted from a partnership firm into a Limited Liability Partnership (LLP). The firm is now known as M S K A & Associates LLP, effective from January 13, 2026. The company confirmed that this is a legal conversion under the LLP Act, 2008, and the audit engagement remains unchanged. The auditor will continue to discharge its duties for the remaining period of its current term.
- Statutory Auditor M S K A & Associates converted to M S K A & Associates LLP effective January 13, 2026
- The conversion was carried out under the provisions of the Limited Liability Partnership Act, 2008
- The ICAI Firm Registration Number for the new entity is 105047W/W101187
- Existing audit engagement and terms remain unchanged for the remaining tenure
Advanced Enzyme Technologies has filed its quarterly compliance certificate under SEBI (Depositories and Participants) Regulations for the period ending December 31, 2025. The certificate, issued by Registrar MUFG Intime India Private Limited, confirms that all dematerialization requests were processed within the mandated timelines. It ensures that physical share certificates received were mutilated, cancelled, and the depository names were updated in the register of members. This filing is a standard administrative requirement and confirms the company's adherence to shareholding record protocols.
- Compliance certificate for the quarter ended December 31, 2025, submitted to BSE and NSE.
- Registrar MUFG Intime India confirmed processing of all dematerialization requests.
- Securities comprised in the certificates are listed on the stock exchanges where earlier shares are listed.
- Confirms mutilation and cancellation of physical certificates after due verification within prescribed timelines.
Advanced Enzyme Technologies Limited has announced the closure of its trading window starting January 01, 2026. This action is taken in accordance with SEBI Insider Trading regulations ahead of the financial results for the quarter and nine months ending December 31, 2025. The window will remain closed for all designated persons until 48 hours after the results are made public. This is a standard compliance procedure for listed companies in India.
- Trading window closure effective from January 01, 2026.
- Closure pertains to financial results for the period ending December 31, 2025.
- Window to reopen 48 hours after the official announcement of results.
Financial Performance
Revenue Growth by Segment
In Q2 FY26, the Human Nutrition segment grew 22% YoY to INR 1,212 million, while Animal Nutrition grew 6% YoY to INR 193 million. The Specialized Manufacturing segment showed the highest growth at 54% YoY, reaching INR 185 million. Overall consolidated revenue for Q2 FY26 grew 26% YoY to INR 1,845 million.
Geographic Revenue Split
For FY 2024-25, international sales accounted for 54% of revenue (up from 50% in FY 2023-24), while domestic sales contributed 46% (down from 50%). Exports, primarily to the US, represent approximately 48-49% of total revenue.
Profitability Margins
Profitability showed significant improvement in Q2 FY26 with PAT margins reaching 24% compared to 23% in Q2 FY25. For the full year FY 2024-25, operating margins were stable around 33-35%, benefiting from lower material and freight costs despite slower recovery in high-margin global markets.
EBITDA Margin
EBITDA margin for Q2 FY26 stood at 33%, a significant increase from 29% in Q2 FY25. This 400 basis point improvement was driven by a 42% YoY increase in absolute EBITDA to INR 601 million, reflecting strong operating leverage as revenue scaled.
Capital Expenditure
The company has planned a capital expenditure of INR 70-80 crore for setting up a new Research and Development (R&D) facility over the next three fiscals. This is expected to be funded entirely through internal accruals and existing liquid surplus of INR 546 crore.
Credit Rating & Borrowing
The company maintains a 'CRISIL A+/Stable' long-term rating and 'CRISIL A1' short-term rating. Borrowing is minimal with a gearing ratio of 0.03 times as of March 31, 2024. It has access to fund-based limits of INR 32.5 crore which remain marginally utilized.
Operational Drivers
Raw Materials
Specific raw material names are not listed, but the company utilizes inputs for fermentation and production of over 68 enzymes and probiotics. Material costs are a primary driver, with margins improving in FY24 due to lower material and freight expenses.
Capacity Expansion
Current total fermentation capacity is 500 cubic meters across 9 manufacturing facilities in India and the US. Expansion is currently focused on the Specialized Manufacturing segment where capacity utilization is increasing to support a 54% YoY revenue growth.
Raw Material Costs
Raw material and freight costs were lower in fiscal 2024, contributing to an increase in operating margin to 34% from 32% in fiscal 2023. The company uses technological innovation to mitigate inflationary pressures on these costs.
Manufacturing Efficiency
Operating efficiency is driven by integrated capabilities across the value chain, from R&D to distribution. The company operates 7 R&D centers to maintain its competitive edge in proprietary product development.
Logistics & Distribution
Distribution is handled through established channels in India and the US. Freight costs significantly impacted margins in FY23 (reducing them to 33%) but saw relief in FY24, aiding margin recovery.
Strategic Growth
Expected Growth Rate
15%
Growth Strategy
Growth will be achieved through a 15% CAGR revenue target by expanding the Specialized Manufacturing segment (currently 10% of revenue), increasing applications for enzymes and probiotics in Human Nutrition, and leveraging 7 R&D centers for new product development. The company also targets inorganic growth through acquisitions, supported by a liquid surplus of INR 546 crore.
Products & Services
The company sells over 400 proprietary products including enzymes, probiotics, bio-catalases, and specialized medicines like serratiopeptidase for human and animal nutrition.
Brand Portfolio
Advanced Enzymes, JC Biotech, Evoxx.
New Products/Services
The company is continuously developing new products from its basket of 68+ enzymes and probiotics, focusing on bio-catalysis and human healthcare applications to drive modest medium-term growth.
Market Expansion
Expansion is targeted in the Specialized Manufacturing segment and through deeper penetration in the US market, which currently accounts for nearly half of the consolidated revenue.
Market Share & Ranking
The company holds a robust market position in the global enzyme industry with a comprehensive product basket and significant fermentation capacity of 500 cubic meters.
Strategic Alliances
The company operates through key subsidiaries including JC Biotech (INR 186 million Q2 revenue) and Evoxx (INR 74 million Q2 revenue) to manage specialized segments and international operations.
External Factors
Industry Trends
The industry is seeing a rise in the application of enzymes, probiotics, and bio-catalases across human and animal nutrition. The company is positioning itself by expanding its specialized manufacturing and R&D capabilities to meet this growing demand.
Competitive Landscape
The company faces intense competition in the domestic market, particularly for products like serratiopeptidase, which keeps margins in the specialized manufacturing segment relatively low at 8-10%.
Competitive Moat
The moat is built on 400+ proprietary products, 7 R&D centers, and 9 manufacturing facilities. This technical expertise and integrated value chain make it difficult for competitors to replicate its specialized enzyme formulations.
Macro Economic Sensitivity
The company is sensitive to global demand shifts, particularly in the human nutrition segment which saw a revenue dip in H1FY25 due to lower demand and an INR 8 crore revenue reversal.
Consumer Behavior
There is a growing demand for probiotics and enzyme-based solutions in human healthcare, which the company is addressing through its largest segment, Human Nutrition (67% of sales).
Geopolitical Risks
Geopolitical turbulence is a risk to the supply chain and export demand, particularly for the 54% of revenue generated from international markets.
Regulatory & Governance
Industry Regulations
Operations are subject to stringent food and drug safety regulations globally. Compliance is critical as any failure could lead to product recalls or discontinuation of business by major customers.
Environmental Compliance
The company is committed to ESG principles to enhance stakeholder confidence and maintain access to capital markets, though specific INR compliance costs are not disclosed.
Taxation Policy Impact
The effective tax rate is approximately 28.5% based on FY25 consolidated figures (INR 534 million tax on INR 1,874 million PBT).
Risk Analysis
Key Uncertainties
Regulatory compliance risks and fluctuations in foreign exchange rates are the primary uncertainties. A significant adverse regulatory action could impact the business risk profile and lead to a rating downgrade if margins fall below 30%.
Geographic Concentration Risk
High geographic concentration in the US market, which accounts for approximately 48-49% of total revenue.
Third Party Dependencies
The company is actively reducing dependency on single suppliers to mitigate supply chain risks arising from geopolitical issues.
Technology Obsolescence Risk
The company mitigates technology risks through continuous R&D investment (INR 70-80 crore planned) and maintaining a portfolio of 400+ proprietary products.
Credit & Counterparty Risk
Receivables quality is generally high, supported by healthy relationships with customers, though the company maintains high working capital (197 days GCA) to support its US operations.